NCT03713190View on ClinicalTrials.gov

Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

February 15, 2020

Study Completion Date

March 15, 2020

Conditions
End Stage Renal Disease
Interventions
COMBINATION_PRODUCT

Empagliflozin

Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.

DRUG

Placebo

A substance without specific pharmacology principles

Trial Locations (1)

56124

Department of Endocrinology and Metabolism, University of Pisa, Pisa

All Listed Sponsors
lead

University of Pisa

OTHER

NCT03713190 - Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD). | Biotech Hunter | Biotech Hunter